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Abstract
Background: Acute pericarditis is inflammation of the pericardium that begins suddenly, is often painful, and causes fluid and blood components to 
enter the pericardial space. Acute pericarditis has numerous causes. However, in developed countries, roughly 80 to 90% of cases are idiopathic; that 
is, no specific cause is identified after routine evaluation. It is assumed that these cases are viral. The remaining 10 to 20% of cases are most commonly 
associated with post–cardiac injury syndromes, connective-tissue diseases, or cancer [1]. The true incidence of the disease is unknown, it is estimated 
that it accounts for 5% of emergency department visits for chest pain in the absence of myocardial infarction [2]. New diagnostic strategies have been 
proposed for the triage of patients with pericarditis and when additional diagnostic investigations are required to perform [3]. Major advances have 
occurred in therapy with the first multicentre randomized clinical trials.Colchicine has been demonstrated as a first-line drug to be added to conventional 
antiinflammatory therapies in patients with a first episode of pericarditis or recurrences [3,4]. The information presented here, also contains a clinical 
case of a patient admited to the cardiology clinic with pericardial effusion in acute pericarditis.
Conclusions: In the field of pericardial diseases there are a limited number of randomized controlled trials. Significant new data have become available 
since 2004, and the new version of recent guidelines published in 2015 have a great impact for clinical practice. 
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Introduction
Pericardial diseases may be either isolated disease or part 
of a systemic disease [4]. The main pericardial syndromes 
that are encountered in clinical practice include pericarditis 
(acute, subacute, chronic and recurrent), pericardial effusion, 
cardiac tamponade, constrictive pericarditis and pericardial 
masses (tab. 1, 2) [3]. In table 1 is presented a partial list of 
diseases that can involve the pericardium. 
Acute pericarditis, defined as symptoms and/or signs 
resulting from pericardial inflammation of no more than 1 
to 2 weeks duration, can occur in a variety of these disea-
ses (denoted by asterisks), but most cases are considered 
idiopathic. The term idiopathic denotes acute pericarditis 
for which no specific cause can be found with routine 
diagnostic testing [5]. But majority of cases includes an 
immune-mediated process that is probably triggered by a 
viral infection in many cases, testing for specific viruses 
is not routine [6]. The etiology that can be found in a spe-
cific setting depends on the epidemiological background. 
Tuberculosis is the leading cause of pericardial diseases 
as well as pericarditis all over the world, being the most 
important etiology in developing countries where tubercu-
losis is endemic and often associated with HIV infection. 
On the contrary, tuberculosis is reported in <5% of cases 
in Western Europe and North America [7].
The true incidence and prevalence of the disease are 
unknown and there are a large number of undiagnosed 
cases. However, it may account for up to 5% of presen-
tations to emergency departments for chest pain and 
up to 0.1% of hospital admissions. In an observational 
study from an urban area in Northen Italy the incidence 
of acute pericarditis was 27,7 cases per 100,000 persons 
per year [8]. A Swedish registry study found an incidence 
rate of 18,0 per 100 000 for pericarditis in the general 
population, in retired US military personnel, the inci-
dence rate of pericarditis is 7,4 per 100 000 [9]. Many 
studies have reported conflicting results on the effect of 
sex on the risk of pericarditis. A recent randomized trial 
found 65% of 1361 patients to be male. Furthermore, 
the incidence rate of acute pericarditis in the general 
adult population was 2- fold among men compared with 
women [10]. Reasons for sex differences in pericardial 
inflammation are unknown, but experimental viral 
studies of myocardial inflammation have suggested 
that although genetic differences have some effect, sex 
hormones are major contributors for sex predisposition. 
Exogenous testosterone increases viral replication and 
inflammation in the heart and gonadectomy inhibits 
cardiac inflammation in experimental viral myocardi-
tis. The in-hospital mortality rate for acute pericarditis 
is estimated at 1.10%. Female sex is associated with 
increased mortality in univariate analysis but was not 
an independent predictor of death in the multivariate 
model [11]. 
Case report
A 50 year old female patient M. was admitted to the 
Cardiologic Clinic on 08.02.2016 with difficulty of breath at 
low/medium physical effort, dull pericardial chest pain which 
was relieved by anterior thoracic bending, periodic cardiac 
palpitations, marked fatigue and light knee pain.
History. The symptoms became evident 2 weeks before 
when the fatigue and dyspnea progressed and the pericardial 
thoracic dull pain appeared along with nagging knee pain. 
During the last year she had 3-4 flu episodes, being liable to 
oral herpes infection, as well. Moreover, the patient has 1st 
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degree anemia for 5-6 years and periodically uses iron medi-
cation for short period courses.
Personal history – normal physical childhood develop-
ment. Profile history – works as a nurse in the emergency 
healthcare (physical strain, reduced sleeping).
Clinical examination showed pale pink skin without pe-
ripheral edema, and absence of jugular veins turgor. Normal 
pulmonary clinical examination. The clinical examination 
of the cardiovascular system showed the increased right 
and left relative cardiac dullness limits. Rhythmic and clear 
cardiac sounds with the cardiac contractions frequency of 84 
bpm, and a blood pressure of 150/90 mmHg. Well-developed 
musculoskeletal system with no pain in joint movement. Light 
hepatomegaly. The thyroid is not palpable. 
Investigations. All biological data was in normal range 
except for the 1st degree anemia (Hemoglobin level 99 g/l, 
red blood cells (RBC) 3,3x10^12/l) with anisocytosis and 
hypochromic RBC (microcytes), with a normal serum iron 
level – 9,9 umol/L, thrombocytes – 412.5x10^9/l, leucocytes 
– 3.8x10^9/l, and the inflammatory markers: erythrocyte 
sedimentation rate (ESR) – 40 mm/h, C-reactive protein 
(CRP) – 24 mg, antistreptolysine O – 200, and a negative 
latex-test. Troponins – negative, creatine kinase- MB (CK-
MB) – 8 U/l, total creatine kinase (CK) – 25 U/l and alkaline 
phosphatase – 227 U/l.
Electrocardiogram (fig. 1): Sinus rhythm with cardiac 
contractions frequency – 82 bpm, normal electrical axis of 
the heart. Flattening of the T waves in all leads. 
Thoracic radiography (fig. 2): Pulmonary area with signs 
of venous stasis. Pulmonary hypertension. Left basal disk 
shaped atelectasis. Bilateral free costo-diaphragmatic sinuses. 
Transversally dilated heart. 
Echocardiography (fig. 3): Ascending Aorta – 34 mm, left 
atrium – 44 mm, left ventricle (LV) – 57 mm, right ventricle 
(RV) – 23 mm, right atrium (RA) – 42 mm,  interventricular 
septum (IVS)  and left ventricular posterior wall (LVPW) – 8 
mm. Pulmonary artery pressure (PAP) – 43 mmHg. Conside-
rable amount of fluid in the pericardium: LVPW – 25 mm, 
lateral wall of left ventricle (LWLV) – 28 mm, RA basal – 22 
mm, anterior wall of right ventricle (AWRV) – 10mm, apex 
-10 mm. Conclusion: Light dilation of LA, RA, LV. Signs of 
RA collapse. Mitral valve insufficiency I-II degree, tricuspid 
valve insufficiency II degree. Preserved cardiac pump function 
(Ejection fraction (EF) – 65%). 
Taking into consideration the clinical data and the in-
vestigations there was established the diagnosis: Exudative 
acute pericarditis, considerable amount of pericardial effu-
sion. Mitral valve insufficiency (II degree), tricuspid valve 
insufficiency (II degree). Heart failure NYHA II. Anemia of 
unknown etiology.
Question No 1: What are the diagnostic criteria of 
acute pericarditis and which one of them is seen in 
the presented patient?
The classic presentation of acute pericarditis, regardless 
of its etiology, is a patient with chest pain that is sharp, ple-
uritic in nature, retrosternal or left-sided in location, that is 
present in more than 85-90% of cases [3]. The pain is often 
exacerbated by lying down and is relieved by sitting up or 
leaning forward. The pain may radiate to the neck, arms, or 
left shoulder, making it difficult to differentiate from the pain 
of myocardial infarction. However, pain that radiates to one 
or both trapezius muscle ridges suggests pericarditis because 
the phrenic nerve innervates these muscles and crosses the 
pericardium as well [12]. Acute chest pain may or may not 
occur in patients with uremic pericarditis or pericarditis 
associated with rheumatologic disorders, although pleuritic 
chest pain may be the initial presentation of systemic lupus 
erythematosus. A pericardial friction rub, which is highly 
Table 1
Etiology of pericardial diseases [3]
A. Infectious causes
Viral (common): Enteroviruses (coxsackieviruses, echoviruses), herpes 
viruses (EBV, CMV, HHV-6), adenoviruses, parvovirus B19 (possible 
overlap with etiologic viral agents of myocarditis).
Bacterial: Mycobacterium tuberculosis (common, other bacterial 
rare), Coxiella burnetii, Borrelia burgdorferi, rarely: Pneumococcus 
spp, Meningococcus spp, Gonococcus spp, Streptococcus spp, Sta-
phylococcus spp, Haemophilus spp, Chlamydia spp, Mycoplasma 
spp, Legionella spp, Leptospira spp, Listeria spp, Providencia stuartii.
Fungal (very rare): Histoplasma spp (more likely in immunocompetent 
patients), Aspergillus spp, Blastomyces spp, Candida spp (more likely 
in immunocompromised host).
Parasitic (very rare): Echinococcus spp, Toxoplasma spp
B. Non-infectious causes
Autoimmune (common): Systemic autoimmune and auto-inflamma-
tory diseases (systemic lupus
erythematosus, Sjögren syndrome, rheumatoid arthritis, scleroder-
ma), systemic vasculitides (i.e. eosinophilic granulomatosis with 
polyangiitis or allergic granulomatosis, previously named Churg-
Strauss syndrome, Horton disease, Takayasu disease, Behçet syndro-
me), sarcoidosis, familia Mediterranean fever, inflammatory bowel 
diseases, Still disease.
Neoplastic: Primary tumours (rare, above all pericardial mesotheli-
oma).
Secondary metastatic tumours (common, above all lung and breast 
cancer, lymphoma).
Metabolic: Uraemia, myxoedema, anorexia nervosa, other rare.
Traumatic and Iatrogenic:
Early onset (rare):
• Direct injury (penetrating thoracic injury, an esophageal perforation).
• Indirect injury (non-penetrating thoracic injury, radiation injury).
Delayed onset: Pericardial injury syndromes (common) such as 
postmyocardial infarction syndrome, postpericardiotomy syndro-
me, posttraumatic, including forms after iatrogenic trauma (e.g. 
coronary percutaneous intervention, pacemaker lead insertion and 
radiofrequency ablation).
Drug-related (rare): Lupus-like syndrome (procainamide, hydralazine, 
methyldopa, isoniazid, phenytoin); antineoplastic drugs (often asso-
ciated with a cardiomyopathy, may cause a pericardiopathy): doxoru-
bicin, daunorubicin, cardiomyopathy, may cause a pericardiopathy): 
doxorubicin, daunorubicin, hypersensitivity pericarditis with eosino-
philia; amiodarone, methysergide, mesalazine, clozapine, minoxidil, 
dantrolene, practolol, phenylbutazone, thiazides, streptomycin, thio-
uracils, streptokinase, p-aminosalicylic acid, sulfadrugs, cyclosporine, 
bromocriptine, several vaccines, GM-CSF, anti-TNF agents.
Other (common): Amyloidosis, aortic dissection, pulmonary arterial 
hypertension and chronic heart failure.
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specific and pathognomonic for acute pericarditis, occurs in 
up to 33% of patients, but its absence does not exclude the di-
agnosis [3]. According to the European Society of Cardiology, 
2015 (ESC), the diagnosis of acute pericarditis is established 
by the presence of at least 2 of the 4 criteria presented in Table 
2 with/ without additional signs. 
The electrocardiogram (ECG) is the most important tool 
in the diagnosis of pericarditis. Typical ECG changes have 
been reported in up to 60% of cases [13]. It may show sinus 
tachycardia and widespread ST-segment elevation which has 
been considered the hallmark of acute pericarditis [14]. The 
ST segment is usually coved upward and lead involvement 
in acute pericarditis is more extensive than reciprocal ST-
segment depression in ischemia. Another recent criteria to 
differentiate acute ST segment elevation myocardial infarction 
(STEMI) from acute pericarditis is the prolongation of the 
QRS complex and shortening of the QT interval in ECG leads 
with ST segment elevation which are not the case in patients 
Fig. 2.  Thoracic radiography of the patient.
Fig. 1.  Electrocardiogram of the patient.
Fig. 3.  The admission day echocardiography examination – considerable amount of fluid  
in the pericardium and signs of RA collapse.
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with pericarditis [15]. PR-depression is another feature in the 
ECG of the patient with pericarditis. According to a study by 
Porela et al. the most common location for PR depression 
was lead II (55.9%), while this ECG finding least likely ap-
peared in lead aVL (2.9%). PR depression in any lead had a 
high sensitivity (88.2%), but fairly low specificity (78.3%) for 
miopericarditis. The combination of PR depressions in both 
precordial and limb leads had the most favorable predictive 
power to differentiate miopericarditis from STEMI (positive 
96.7% and negative power 90%) [16]. A useful data suggests 
how to distinguish by ECG acute pericarditis and benign early 
repolarization as both conditions are associated with concave 
ST elevation. Thus, the vertical height of the ST segment 
elevation (from the end of the PR segment to the J point) is 
measured and compared to the amplitude of the T wave in 
V6. A ratio of > 0.25 suggests pericarditis and ratio of < 0.25 
suggests benign early repolarization [17].
Other mandatory checks besides auscultation and ECG 
according to the latest European guidelines on pericardial 
diseases are echocardiography to rule out effusion conco-
mitant heart disease or signs of myocarditis. Transthoracic 
echocardiogram (TTE) is the first-line imaging test to 
detect pericardial effusion and tamponade physiology. 
Although many patients with acute pericarditis may appear 
to have normal echocardiographic results, the presence 
of an effusion is consistent with acute pericarditis [18]. 
Other findings may include increased pericardial bright-
ness, pericardial thickening, and abnormal septal bounce, 
suggesting early constriction. A pericardial effusion can be 
trivial to large and localized, loculated, or circumferential. 
Importantly, tamponade physiology can be seen in 3% of 
patients. Intrapericardial fibrinous strands suggest either an 
inflammatory etiology or clotted blood. TTE may also help 
differentiate acute pericarditis from myocardial ischemia or 
injury by excluding wall motion abnormalities, even though 
a small percentage of patients with acute pericarditis (5%) 
will demonstrate segmental wall motion abnormalities. If 
the results of TTE are negative or equivocal in a patient 
suspected to have acute pericarditis with poor prognostic 
signs, or evidence of hemodynamic compromise, the most 
sensitive subsequent test is CMR, which shows edema and 
inflammation as well as features of constrictive physiology. 
The choice of CT or CMR should be based on the specific 
clinical question according to the strength of these mo-
dalities. The following are scenarios in which additional 
imaging with CT or CMR may be considered:
- Inconclusive echocardiographic findings and ongoing 
clinical concern;
- Failure to respond promptly to anti-inflammatory 
therapy;
- Atypical clinical presentation;
- Search for a specific cause (i.e., malignancy or tubercu-
losis);
- Suspicion of constrictive pericarditis or effusive con-
strictive pericarditis;
- Associated trauma (penetrating injury, chest injury); 
and
- Acute pericarditis in the setting of acute myocardial 
infarction, neoplasm, lung or chest infection, or pan-
creatitis [19].
A chest X-ray is generally normal in patients with acute 
pericarditis since an increased cardiothoracic ratio only occurs 
with pericardial effusions exceeding 300 ml [20].
Elevation of markers of inflammation (i.e. CRP and ESR), 
as well as elevation of the white blood cell count) is a common 
and supportive finding in patients with acute pericarditis and 
may be helpful for monitoring the activity of the disease and 
efficacy of therapy. Patients with concomitant myocarditis 
may present with an elevation of markers of myocardial injury 
(i.e., CK, troponin) [21].
Our patient presented 2 of those 4 mentioned criteria: 
pericardial type pain and pericardial effusion (on TTE and 
thoracic radiography) and the additional signs found were 
the inflammatory markers – elevated ESR and CRP levels. 
Electrocardiogram didn't show typical signs, only flattening 
of the T waves in all leads.
Table 2
Definitions and diagnostic criteria for pericarditis [3]
Pericarditis Definition and diagnostic criteria
Acute Inflammatory pericardial syndrome to be dia-
gnosed with at least 2 of the 4 following criteria:
(1) pericarditic chest pain (> 85- 90% of cases)
(2) pericardial rubs ( ≤33% of cases)
(3) new widespread ST-elevation or PR depre-
ssion on ECG (60% of cases)
(4) pericardial effusion (new or worsening) 
(60% of cases)
Additional supporting findings:
- Elevation of markers of inflammation (i.e. 
C-reactive protein, erythrocyte sedimentation 
rate, and white blood cell count);
- Evidence of pericardial inflammation by an 
imaging technique (CT, CMR).
Incesant Pericarditis lasting for > 4-6 weeks but <3 mon-
ths without remission.
Recurrent Recurrence of pericarditis after a documen-
ted first episode of acute pericarditis and a 
symptom-free interval of 4–6 weeks or longer 
(usually within 18-24 months).
Chronic Pericarditis lasting for >3 months.
Question No 2: What is the possible etiology of peri-
carditis in this patient?
In this patient there were evaluated the following possible 
causes of acute pericarditis:
- Pericarditis in the context of autoimmune diseases 
(System Lupus Erythematosus, Rheumatoid arthritis, 
Spondyloarthropathy, etc.), because the patient had joint 
pain when moving and resting.
- Myxedematous pericarditis
- Viral pericarditis
Pericarditis in the context of systemic diseases was exclu-
ded through the evaluation of systemic autoimmune markers, 
which happened to be negative (tab. 3).
Myxedematous pericarditis was excluded through the 
evaluation of thyroid hormones, which happened to be in 
normal range and the thyroid ultrasound examination did 


























Frequently, the cause of pericarditis cannot be found, 
the idiopathic pericarditis having an estimated incidence of 
85 – 90 % [22], but many of these cases are probably viral, 
viral pericarditis being the most frequent cause of infectious 
pericarditis. Most likely, in the presented case report, the 
cause of acute pericarditis remains to be viral, as the patient 
had episodes of flu in the previous period of time, that went 
through with catarrhal signs (persistent rhinorrhea, viral 
conjunctivitis) and had a rapid regression. Moreover, denoting 
that the patient is liable to oral herpes infection.
Question No 3: Is pericardiocentesis a treatment 
option?
In correspondence with the management algorithm 
of pericardial effusion mentioned in the ESC 2015 guide 
for pericarditis, pericardiocentesis or cardiac surgery 
is a 1C class indication in case of cardiac tamponade, 
or in case of symptomatic moderate – large pericardial 
effusion which does not respond to medication or in case 
of unknown bacterial or neoplastic etiology suspecting 
(fig. 4). In this case there are no indications for pericar-
diocentesis, because the patient was hemodynamically 
stable, without paradox pulse, besides the echocardio-
graphic signs of RA collapse. The diagnosis of cardiac 
tamponade is a more clinical one and in the absence of 
hypotension, paradox pulse cannot be established, as well 
as, during the clinical examination and from the history 
there was not appreciated the coexistence of a neoplastic 
process. An eventual pericardiocentesis was difficult to 
perform because of the possible complications and the 
technique – since the pericardial fluid was located in the 
posterior, hard to access space.
Question No 4: What would be the appropriate treat-
ment in this patient?
The medication choice has to deal with the patients’ 
history (contraindications, anterior efficacy or medication 
Fig. 4.  A simplified algorithm for pericardial effusion triage and management [3].
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side effects), the accompanying diseases [23]. The first non-
pharmacologic precaution is avoiding physical effort until 
stabilization of CRP and the symptoms. Acute idiopathic 
pericarditis is a self-limited disease with a recurrence rate 
after an initial episode from 15 to 30% [24]. Because of 
its excellent safety profile, is preferred ibuprofen (600 mg 
every 8h). Acetylsalicylic acid (ASA), 750–1000 mg every 
8h daily in divided doses, is an alternative and often pre-
ferable in patients who require ASA for other indications, 
as in patients with pericarditis after myocardial infarction 
because other NSAIDs have delayed infarct healing in 
animal models and are associated with an increased risk 
of future coronary events in this population In either case, 
gastric protection in the form of a proton pump inhibitor 
should be provided [25]. Colchicine is recommended at low, 
weight-adjusted doses (0.5 mg once (<70 kg) or 0.5 mg b.i.d. 
(≥70 kg)) to improve the response to medical therapy and 
significantly reduced the rate of subsequent recurrences of 
pericarditis in patients with multiple recurrences. Taken 
together with results from other randomized controlled 
trials, colchicine should be probably regarded as a first-line 
treatment for either acute or recurrent pericarditis in the 
absence of contraindications or specific indications [26]. 
Corticosteroids should be considered as a second option 
in patients with contraindications and failure of aspirin or 
NSAIDs because of the risk of favoring the chronic evolu-
tion of the disease and promoting drug dependence [27].
Thus, in this patient was started empiric treatment (accor-
ding to the algorithm in fig. 5) with ibuprofen – 1600 mg/day 
divided in 4 doses and colchicine – 1 mg, ½ tablet x 2/24h, 
beta – blockers and diuretics. At the 7th day from admission 
the echocardiography examination was repeated (Fig. 6) to 
evaluate the pericardial effusion dynamics, where there was 
found an essential reduction of the pericardial effusion: LVPW 
– 9 mm, LWLV – 8 mm, RA basal – 3 mm, AWRV – 3mm, 
apex – 3mm. As well, the inflammatory markers reduced: 
ESR – 20 mm/h, CRP – 6 mg.
Question No 5: How long does the treatment take?
The ibuprofen recommended treatment duration is 1 – 2 
weeks (the patient administered ibuprofen being in the ho-
spital for 8 days, and at discharge she was recommended to 
continue administering it 6 more days)
Question No 6:  Why is the prolonged colchicine 
treatment necessary?
According to the recent data the simultaneous adminis-
tration of colchicine for 3 months favors a rapid regression of 
the symptoms and with fewer recurrences in comparison with 
patients which administered only NSAIDs and/or colchicine 
less time [28]. The recurrence rate after an initial episode of 
pericarditis may increase to 50% after a first recurrence of 
acute pericarditis in patients not treated with colchicine [29].
Question No 7: What is the prognosis in acute peri-
carditis?
The prognosis for acute pericarditis is usually good. 
Although mortality in idiopathic/viral pericarditis is low, 
purulent pericarditis is always fatal if untreated and carries a 
mortality of approximately 40% even when treated [29]. In the 
acute pericarditis it is important to consider the high risk fac-
tors for development of complications during the pathologic 
evolution (cardiac tamponade, recurrence and constriction) 
[30]. The risk factors associated with a negative prognosis 
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Fig. 6  The echocardiography examination at the 7th day from admission.
are: severe fever (>38°C), subacute evolution, evidence of 
pericardial fluid in significant amount (> 20 mm), cardiac 
tamponade, the treatment response absence during a 7 day 
NSAIDs course, or other minor risk factors as: pericarditis 
in association with myocarditis, immunosuppression, trau-
ma or oral anticoagulation treatment. Perhaps 15% to 30% 
of patients with apparent idiopathic acute pericarditis who 
respond satisfactorily to treatment suffer a relapse. Genetic 
disorders of the immune system underlie some cases of re-
current pericarditis. A recent study found that 8 of 131 (6.1%) 
patients thought to have recurrent idiopathic pericarditis had 
mutations of the TNFRSF1A gene that causes tumor necrosis 
factor receptor-1–associated periodic syndrome (TRAPS), 
25 a monogenic disorder resulting in dysfunction of the 
innate immune system with periodic fever, rash, abdominal 
pain, periorbital edema, and polyserositis with pericarditis. 
Patients with TRAPS respond to corticosteroids but not 
to colchicine [31]. In another report, 4 of 30 patients with 
recurrent pericarditis refractory to colchicine were found to 
have TNFRSF1A mutations. A report that human leukocyte 
antigen allel patterns are associated with recurrent pericarditis 
also supports a role of genetic variation in innate immunity as 
an underlying determinant. The extent to which TRAPS and 
other innate immune disorders are responsible for recurrent 
pericarditis merits additional research [32].
In the presented patient there was found a single risk 
factor – significant amount of pericardial fluid which had a 
good response to the administered treatment. The majority 
of patients with acute pericarditis have a long term favorable 
prognosis. Constrictive pericarditis can appear in < 1% of 
acute idiopathic pericarditis cases, in about 2 – 5 % of au-
toimmune pericarditis and about 20 – 30 % of the bacterial 
ones, especially tuberculous [33].
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